On October 7, 2025, Aimed Alliance sent a follow-up letter to the U.S. Food and Drug Administration (FDA) regarding the…
Aimed Alliance submitted a comment to the Oregon Prescription Drug Affordability Board (PDAB) urging it to maintain a careful, evidence-based…
Aimed Alliance sent a letter to Colorado Representative Ken DeGraaf’s regarding his special session bill “Prescription Drug Benefit Information Transparency”…
Aimed Alliance has published a new resource highlighting pharmacy benefit manager (PBMs) practices and proposed reforms to ensure transparency in…
Following a May court ruling that pharmaceutical manufacturers must receive Health Resources and Services Administration (HRSA) approval before replacing upfront…
Beginning in January 2026, the Centers for Medicare & Medicaid Services (CMS) will launch the Wasteful and Inappropriate Service Reduction…
On July 28, Aimed Alliance sent a letter to the Centers for Consumer Information and Insurance Oversight (CCIIO) and the…
Prior to the Maryland Prescription Drug Affordability Board’s July meeting to conduct cost affordability reviews for Farxiga and Jardiance, Aimed…
On July 4, 2025, President Trump signed the One Big Beautiful Bill Act into law, notably without a controversial provision…
Washington, D.C. — June 30, 2025 — The not-for-profit Aimed Alliance, released a comprehensive new report analyzing how state policies…